UNDATED (AP)— Michigan lawmakers plan to save money in the state's Medicaid program by limiting the use of popular weight loss drugs, making them available only to people with diabetes and those who are classified as morbidly obese.
Coverage for obesity will only be allowed after other weight loss interventions have failed to prevent higher-cost bariatric surgery. The state's Medicaid program covers GLP-1 drugs like Ozempic and Mounjaro for Type-2 diabetes, as required under federal guidelines.
Michigan had approved coverage in 2022 for those seeking GLP-1s for obesity. Under the new state budget, appropriations for GLP-1 drugs would be reduced by $240 million.
